Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
Altimmune management will host a conference call at
Conference Call Information:
Date: | |
Time: | |
(800) 225-9448 | |
International Dial-in: | (203) 518-9708 |
Conference ID: | ALTQ122 |
Webcast: | https://edge.media-server.com/mmc/p/j5i9f735 |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor and Media Contact:
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
Source: Altimmune, Inc